extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
3e2215c87c
commit
701632487d
5 changed files with 64 additions and 1 deletions
|
|
@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
|
|||
|
||||
Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon's 192K patient analysis found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women. This adds to the multi-organ protection thesis by quantifying sex-specific effects and demonstrating that adherence is the binding variable—benefits scale dramatically with consistent use.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -83,6 +83,12 @@ WHO's conditional recommendation requiring behavioral therapy combination provid
|
|||
|
||||
Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon data shows benefits scale dramatically with adherence: for diabetes indication, medical cost growth is 6 points lower at 30 months but 9 points lower with 80%+ adherence. For weight loss indication, cost growth is 3 points lower at 18 months but 7 points lower with consistent use. This confirms that low persistence rates directly undermine the economic case, as the cost savings require sustained use.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so
|
|||
|
||||
The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
|
||||
|
||||
Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects but comes from a population with better coverage than the general market. The 80%+ adherent cohort shows the strongest effects across all outcomes, suggesting that populations with coverage barriers would see substantially worse real-world outcomes, reinforcing the affordability-persistence link.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-receptor-agonists-reduce-female-ovarian-cancer-incidence-by-50-percent-in-real-world-claims-data.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
|
||||
"glp-1-receptor-agonists-reduce-female-ovarian-cancer-incidence-by-50-percent-in-real-world-claims-data.md:set_created:2026-03-18"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-reduce-female-ovarian-cancer-incidence-by-50-percent-in-real-world-claims-data.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -49,3 +53,12 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
|
|||
EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
|
||||
|
||||
flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed commercial health claims data from 192,000+ GLP-1 users in multi-year study released January 13, 2026
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs. 6% for non-users
|
||||
- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
|
||||
- Adherent users (80%+): 47% MACE reduction for women, 26% for men
|
||||
- GLP-1 users also showed lower rates of osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations
|
||||
|
|
|
|||
Loading…
Reference in a new issue